CN101524421B - Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases - Google Patents
Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN101524421B CN101524421B CN 200810136660 CN200810136660A CN101524421B CN 101524421 B CN101524421 B CN 101524421B CN 200810136660 CN200810136660 CN 200810136660 CN 200810136660 A CN200810136660 A CN 200810136660A CN 101524421 B CN101524421 B CN 101524421B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- prescription
- folium
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract description 9
- 208000026106 cerebrovascular disease Diseases 0.000 title abstract description 7
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract description 5
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 46
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 46
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 35
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 35
- 241000218628 Ginkgo Species 0.000 claims description 44
- 210000002216 heart Anatomy 0.000 claims description 21
- 210000004556 brain Anatomy 0.000 claims description 20
- 241000219780 Pueraria Species 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 abstract description 25
- 230000008569 process Effects 0.000 abstract description 22
- 239000002775 capsule Substances 0.000 abstract description 21
- 239000008187 granular material Substances 0.000 abstract description 21
- 239000003826 tablet Substances 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 239000007788 liquid Substances 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 6
- 239000006187 pill Substances 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 239000003405 delayed action preparation Substances 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- -1 pulvis Substances 0.000 abstract description 2
- 244000046146 Pueraria lobata Species 0.000 abstract 4
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 4
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 2
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 2
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 2
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 2
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 2
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 2
- 244000194101 Ginkgo biloba Species 0.000 abstract 2
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract 2
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 2
- 208000026435 phlegm Diseases 0.000 abstract 2
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000002110 toxicologic effect Effects 0.000 abstract 1
- 231100000027 toxicology Toxicity 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- 239000000843 powder Substances 0.000 description 30
- 230000006837 decompression Effects 0.000 description 24
- 238000005516 engineering process Methods 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 24
- 239000002552 dosage form Substances 0.000 description 21
- 239000002671 adjuvant Substances 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 238000001035 drying Methods 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 238000011049 filling Methods 0.000 description 16
- 238000010171 animal model Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 210000004165 myocardium Anatomy 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 208000029078 coronary artery disease Diseases 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 201000006474 Brain Ischemia Diseases 0.000 description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000031225 myocardial ischemia Diseases 0.000 description 7
- 206010008118 cerebral infarction Diseases 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 238000002481 ethanol extraction Methods 0.000 description 5
- 229960002479 isosorbide Drugs 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 244000132619 red sage Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010060965 Arterial stenosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 241000237970 Conus <genus> Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241001072909 Salvia Species 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GPYKKBAAPVOCIW-HSASPSRMSA-N (6r,7s)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 GPYKKBAAPVOCIW-HSASPSRMSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 101000654245 Homo sapiens Succinate dehydrogenase assembly factor 2, mitochondrial Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100031715 Succinate dehydrogenase assembly factor 2, mitochondrial Human genes 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and a preparing process thereof, mainly containing one or more of Salvia miltiorrhiza, folium ginkgo, panax notoginseng, kudzuvine root Pueraria lobata, rhizoma ligustici wallichii, hawthorn and lotus leaf. The preparation method comprises the steps of selecting one or more of the Salvia miltiorrhiza, thefolium ginkgo, the panax notoginseng, the kudzuvine root Pueraria lobata, the rhizoma ligustici wallichii and the hawthorn and lotus leaf, decocting, extracting active ingredients and concentrating the extracting solution to a certain concentration to obtain the Chinese traditional medicine preparation. In addition, the concentrated solution can be further made into capsules, tablets, granules, oral liquid, pills, pulvis, injection and sustained and controlled release preparations. Toxicologic and pharmacologic agent experiments show that the invention has no toxic side effect, is safe to use, has the functions of promoting blood circulation, remove blood stasis, reducing fat, freeing channels and eliminating phlegm and is suitable for phlegm stasis internal-block type cardiovascular and cerebrovascular diseases.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation and preparation technology thereof, particularly contain in Radix Salviae Miltiorrhizae and Radix Notoginseng, Folium Ginkgo, Radix Puerariae, Rhizoma Chuanxiong, Fructus Crataegi, the Folium Nelumbinis one or more, a kind of heart and brain profit of its mixing or separately extraction is led to preparation, and preparation technology.
Background technology
Cardiovascular disease is important clinically common frdquently encountered disease, has anxious, the characteristics such as change of illness state is fast, mortality rate height of morbidity.Coronary heart disease, hypertensive cardiopathy are sick kinds of painstaking effort tubing that American-European countries sees more, and according to the interrelated data statistics, the U.S. had 6,080,000 people to suffer from coronary heart disease in 1988, and about 540,000 people are therefore sick and dead.In China since the fifties in last century; The M & M of these two kinds of diseases is also rising; Wherein Incidence of CHD is 0.6% to 14.29% not wait; Ordinary circumstance is that developed regions are higher, and is remote lower with backward areas, explains that this type of disease and people's living standard has certain proportional relationship.Indicating that this type of disease is just becoming a serious killer of China's people's life.
Cerebrovascular is all very high disease of a kind of sickness rate, mortality rate and disability rate.China has 1 people dead per 15 seconds because of cerebrovascular; Have 1 people to disable because of cerebrovascular per 22 seconds, and according to our health ministry statistics, the annual morbidity of China in 1997 reaches 2,00/,100,000; Suffer from the patient and surpass 3,000,000 people; The first place of having leapt to all kinds of diseases because of apoplexy death person, about 3/4 in various degree disability brings huge burden and influence for family and society among the survivor.The sickness rate of middle-aged and elderly people is the highest.The No.1 killer who now cerebrovascular disease has been called middle-aged and elderly people.If transient ischemic attack is treatment in time not, the mortality rate in 5 years reaches more than 40%, and this is breakneck.
As far back as middle 1960s, be used for treating the blood supply insufficiency that causes owing to angiostenosis with regard to the peripheral blood vessel that has people's exploration ground that metal rack is inserted animal.Late 1980s, stent endoprosthesis is used for clinical, begins to get into this field of treatment cerebrovascular disease the nineties, and the scope of application has stricture of artery, dissecting aneurysm, aneurysm and arteriovenous fistula.Get into 21 century; Treatment and prevention as ischemic diseases; The ongoing in the world as fire of the interventional therapy of stricture of artery is like naphthalene, and big cities such as domestic Beijing, Shanghai, Guangzhou extensively apply to clinical, for the treatment and the prevention of ischemic cerebrovascular provides advanced treatment means.
Summary of the invention
The objective of the invention is to provide a kind of Chinese medicine preparation of treating cardiovascular and cerebrovascular disease: sharp logical preparation of heart and brain and preparation technology thereof.
This heart and brain profit proposed by the invention is led to preparation, mainly contains in Radix Salviae Miltiorrhizae and Folium Ginkgo, Radix Notoginseng, Radix Puerariae, Rhizoma Chuanxiong, Fructus Crataegi, the Folium Nelumbinis one or more.
Below be to introduce to inventing selected Chinese medicine and extract thereof:
Radix Salviae Miltiorrhizae has inhibitory action to the central nervous system, and the ischemia brain is had protective effect; Immune system there is the immune effect of adjusting, blood circulation is had microcirculation improvement, improve hemorheology; Anticoagulant, activation fibrinolytic, anticoagulant, antithrombotic form, and stablize erythrocyte membrane; Blood pressure lowering, expansion blood vessel; Blood fat reducing, prevent and treat effect such as atherosclerosis, Radix Salviae Miltiorrhizae can coronary artery dilator, increases arterial flow; Strengthen myocardial contraction; Alleviate the damage of acute ischemia and myocardial ischemia-reperfusion; Improve the anti-ability of itching that lacks of ischemic myocardium; The former synthetic and cardiac muscle fiber propagation of antagonism cutin, the reparation and the protection cardiac function that quicken myocardial ischemia and damage are so be widely used in the rescue and the treatment of coronary heart disease, myocardial infarction, angina pectoris, infantile viral myocarditis, hepatitis gravis, hemorrhagic shock.In the pharmacologically active of Radix Salviae Miltiorrhizae, fat-soluble TANSHINONES with the antibacterial action be main, have antiinflammatory, antitumor action concurrently, and the water-soluble phenolic constituents is main with the activity of the heart, cerebrovascular aspect.
The effective ingredient that extracts in the Folium Ginkgo is mainly ginkgetin glycosides and ginkgolide, acts on ischemic treatment of cerebral mechanism: improve hemorheology, be beneficial to microcirculatory unobstructed; Increase the CBFV of cerebral ischemia hemisphere, increase LCBF's supply; Improve the brain cortex hormone function, correct the ischemia injury of brain electricity, promote the recovery of function of nervous system etc.
Radix Notoginseng is mainly used in treatment haematemesis, epistaxis, traumatic hemorrhage, treating swelling and pain by traumatic injury, is used to treat coronary heart disease, diabetes, antianginal, antithrombotic etc. in recent years, and saponin component is the main volume of a Radix Notoginseng physiologically active ingredient.Be mainly reflected in the following aspects: one, to the influence of cardiovascular system: reduce myocardial oxygen consumption, improve myocardial ischemia; Arrhythmia; Blood fat reducing prevents atherosclerosis, and blood vessel dilating brings high blood pressure down, shock.Two, to the influence of cerebrovascular system: expansion of cerebral vascular, reduce cerebral vascular resistance, the cerebral blood flow increasing amount is improved the brain blood circulation; Experimental cerebral ischemia there is protective effect.
The total flavones of Radix Puerariae, particularly Radix Puerariae can make cerebral blood flow significantly increase, and cerebral vascular resistance reduces.And vascular smooth muscle had tangible relexation, puerarin can make that the speed of heartbeat slows down, myocardial contraction strengthens, aortic pressure reduces, but do not reduce ischemic region CC blood flow.
Rhizoma Chuanxiong is through antiplatelet aggregation, blood vessel dilating, reduction WBV, and effects such as adjustment TXA2/PGL2 reach anti thrombotic action.Diseases such as prevention and treatment coronary heart disease, pulmonary heart disease, cerebral thrombosis, renal failure.Rhizoma Chuanxiong extract can make the ET level descend, and can expand little artery and vein, indirect inhibition
Fructus Crataegi; Particularly Fructus Crataegi total flavones can increase coronary flow anti-experimental character myocardial ischemia; Effects such as anti-heart string disppointment, Fructus Crataegi total flavones no matter in the body or treated in vitro all can significantly suppress rabbit platelet aggregation property, this control to cardiovascular disease such as coronary heart disease obviously is that useful mountain nuclear energy makes vasodilation; Help to remove local pound blood state, and the effect of shrinking the uterus, promoting uterine involution is arranged.
Alkaloid in the Folium Nelumbinis, particularly Folium Nelumbinis has the reduction effect to the blood fat in the blood.Folium Nelumbinis is the food of " medicine-food two-purpose "; The Flavonoid substances that is rich in the Folium Nelumbinis; Be the scavenger of most of oxygen-derived free radicals, can improve the vigor of SOD (superoxide dismutase), reduce the generation of MDA (MDA malonaldehyde) and OX-LDL (OxLDL ELISA); It can increase coronary flow, and experimental myocardial infarction is had antagonism; Acute myocardial ischemia there is protective effect; Treatment coronary heart disease, hypertension etc. there is remarkable result; To reducing diastolic pressure; Preventing and treating arrhythmia, cardiovascular diseases etc. also plays an important role; Therefore lotus flavone is one type of material extremely valuable and leaved for development, and it both can be used as the crude drug of cardiovascular disease, also can be widely used in functional food, health food and the beverage.In addition, another big type of active substance-alkaloid in the Folium Nelumbinis, physiologically active is remarkable, has effects such as tangible blood fat reducing, antiviral.
Technical scheme of the present invention is following:
" part " that relates among the present invention all is meant " part by weight ratio ".
The sharp logical preparation of heart and brain is the medicament of being processed by following Chinese medicine raw materials by weight proportion:
Radix Salviae Miltiorrhizae 5-150 part, Radix Notoginseng 0-50 part, Folium Ginkgo 5-80 part,
Radix Puerariae 0-150 part, Rhizoma Chuanxiong 0-150 part, Fructus Crataegi 0-150 part,
Folium Nelumbinis 5-150 part.
The sharp logical preparation of heart and brain is the medicament of being processed by following Chinese medicine raw materials by weight proportion:
Radix Salviae Miltiorrhizae 5-150 part, Radix Notoginseng 3-50 part, Folium Ginkgo 5-80 part,
Radix Puerariae 5-150 part, Rhizoma Chuanxiong 5-150 part, Fructus Crataegi 5-150 part,
Folium Nelumbinis 5-150 part.
The sharp logical preparation of heart and brain is the medicament of being processed by following Chinese medicine raw materials by weight proportion:
Radix Salviae Miltiorrhizae 5-50 part, Folium Ginkgo 5-50 part, Radix Notoginseng 3-50 part,
Radix Puerariae 5-50 part, Rhizoma Chuanxiong 5-50 part, Fructus Crataegi 5-50 part,
Folium Nelumbinis 5-50 part.
Its preparation technology of the sharp logical preparation of heart and brain,
Choose various raw material of Chinese medicine extracting in water effective ingredient respectively;
Choose various raw material of Chinese medicine respectively and add the alcohol extraction effective ingredient;
The effective ingredient that extracts separately or after mixing, is added adjuvant, process preparation.
Technology 1-1: choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Folium Nelumbinis respectively, decocte with water secondary, each 1-2 hour, collecting decoction; Filter, filtrate decompression is condensed into thick paste, drying; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Technology 1-2: choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Radix Notoginseng, Radix Puerariae, Rhizoma Chuanxiong, Fructus Crataegi respectively, decocte with water secondary, each 1-2 hour; Collecting decoction filters, and filtrate decompression is condensed into thick paste; Dry; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Technology 1-3: choose respectively in Radix Salviae Miltiorrhizae, Folium Ginkgo, Radix Notoginseng, Radix Puerariae, Rhizoma Chuanxiong, Fructus Crataegi, the Folium Nelumbinis one or more or all, decocte with water secondary, each 1-2 hour; Collecting decoction filters, and filtrate decompression is condensed into thick paste; Dry; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Technology 2-1: choose Radix Salviae Miltiorrhizae, Folium Nelumbinis respectively, the decocte with water secondary, each 1-2 hour, collecting decoction filtered, and filtrate decompression is condensed into thick paste, and drying is ground into fine powder, and is subsequent use; Choose Folium Ginkgo, add 6-10 and doubly measure 60% ethanol extraction secondary, each 1-2 hour, filter, decompression filtrate recycling ethanol is condensed into the thick paste shape, and drying is ground into fine powder; Merge with above-mentioned fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Technology 2-2: choose Radix Salviae Miltiorrhizae, Radix Notoginseng, Rhizoma Chuanxiong respectively, the decocte with water secondary, each 1-2 hour, collecting decoction filtered, and filtrate decompression is condensed into thick paste, and drying is ground into fine powder, and is subsequent use; Choose Folium Ginkgo, Radix Puerariae, Fructus Crataegi, add 6-10 and doubly measure 60% ethanol extraction secondary, each 1-2 hour, filter, decompression filtrate recycling ethanol is condensed into the thick paste shape, and drying is ground into fine powder; Merge with above-mentioned fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Technology 2-3: choose in Radix Salviae Miltiorrhizae, Radix Notoginseng, Rhizoma Chuanxiong, the Folium Nelumbinis one or more respectively, the decocte with water secondary, each 1-2 hour, collecting decoction filtered, and filtrate decompression is condensed into thick paste, and drying is ground into fine powder, and is subsequent use; Choose in Folium Ginkgo, Radix Puerariae, the Fructus Crataegi one or more, add 6-10 and doubly measure 60% ethanol extraction secondary, each 1-2 hour, filter, decompression filtrate recycling ethanol is condensed into the thick paste shape, and drying is ground into fine powder; Merge with above-mentioned fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Above-mentioned technology can in seven kinds of Radix Salviae Miltiorrhizaes, Folium Ginkgo, Radix Notoginseng, Radix Puerariae, Rhizoma Chuanxiong, Fructus Crataegi, Folium Nelumbinis, reduce one or several operate.
Multiformity in view of pharmaceutical dosage form and production technology; And consider acceptance and the method for using of patient to medicine, composite reagent of the present invention can be processed capsule, tablet, granule, oral liquid, injection, pill, powder, injection, sustained-release preparation by above-mentioned prescription and Technology thereof.In view of pharmaceutical dosage form and the needs that produce to use, can be on the basis of above-mentioned prescription reasonable pharmaceutic adjuvants such as absorb fillers, excipient, pH value regulator, correctives, cosolvent, antioxidant, to satisfy drug manufacture and use.
Advantage of the present invention: cost is low, drug effect is high, have no side effect.
The specific embodiment:
Prescription one:
25 parts of Radix Salviae Miltiorrhizaes, 15 parts of Folium Ginkgos, 3 parts of Radix Notoginseng,
25 parts of Radix Puerariaes, 20 parts of Rhizoma Chuanxiongs, 25 parts of Fructus Crataegis,
20 parts on Folium Nelumbinis.
Prescription two:
25 parts of Radix Salviae Miltiorrhizaes, 15 parts of Folium Ginkgos, 3 parts of Radix Notoginseng,
25 parts of Radix Puerariaes, 20 parts of Rhizoma Chuanxiongs, 25 parts of Fructus Crataegis.
Prescription three:
50 parts of Radix Salviae Miltiorrhizaes, 15 parts of Folium Ginkgos, 3 parts of Radix Notoginseng.
25 parts of Radix Puerariaes, 20 parts of Rhizoma Chuanxiongs,
Prescription four:
25 parts of Radix Salviae Miltiorrhizaes, 30 parts of Folium Ginkgos, 3 parts of Radix Notoginseng.
25 parts of Radix Puerariaes,
Prescription five:
25 parts of Radix Salviae Miltiorrhizaes, 15 parts of Folium Ginkgos, 30 parts of Radix Notoginseng.
Prescription six:
120 parts of Radix Salviae Miltiorrhizaes, 60 parts of Folium Ginkgos
Prescription seven:
25 parts of Radix Salviae Miltiorrhizaes, 15 parts of Folium Ginkgos, 25 parts of Fructus Crataegis.
Prescription eight:
25 parts of Radix Salviae Miltiorrhizaes, 15 parts of Folium Ginkgos, 20 parts of Rhizoma Chuanxiongs.
Prescription nine:
25 parts of Radix Salviae Miltiorrhizaes, 15 parts of Folium Ginkgos, 25 parts of Radix Puerariaes.
Prescription ten:
25 parts of Radix Salviae Miltiorrhizaes, 15 parts of Folium Ginkgos, 20 parts on Folium Nelumbinis.
Effect of the present invention is seen following experimental example:
Experimental example 1: the sharp wildcard side of heart and brain causes the protective effect research of rat heart muscle ischemia to the ligation arteria coronaria.
Process recipes:
Prescription one the 1st kind of technology, choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Radix Notoginseng, Radix Puerariae, Rhizoma Chuanxiong, Fructus Crataegi, Folium Nelumbinis respectively, decocte with water secondary, each 1-2 hour; Collecting decoction filters, and filtrate decompression is condensed into thick paste; Dry; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Prescription one the 2nd kind of technology, choose Radix Salviae Miltiorrhizae, Radix Notoginseng, Rhizoma Chuanxiong, Folium Nelumbinis respectively, the decocte with water secondary, each 1-2 hour, collecting decoction filtered, and filtrate decompression is condensed into thick paste, and drying is ground into fine powder, and is subsequent use; Choose Folium Ginkgo, Radix Puerariae, Fructus Crataegi, add 6-10 and doubly measure 60% ethanol extraction secondary, each 1-2 hour, filter, decompression filtrate recycling ethanol is condensed into the thick paste shape, and drying is ground into fine powder; Merge with above-mentioned fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Prescription two, choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Radix Notoginseng, Radix Puerariae, Rhizoma Chuanxiong, Fructus Crataegi respectively, decocte with water secondary, each 1-2 hour; Collecting decoction filters, and filtrate decompression is condensed into thick paste; Dry; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Prescription three, choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Radix Notoginseng, Radix Puerariae, Rhizoma Chuanxiong respectively, decocte with water secondary, each 1-2 hour; Collecting decoction filters, and filtrate decompression is condensed into thick paste; Dry; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Prescription four: choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Radix Notoginseng, Radix Puerariae respectively, decocte with water secondary, each 1-2 hour, collecting decoction; Filter, filtrate decompression is condensed into thick paste, drying; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Prescription five: choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Radix Notoginseng respectively, decocte with water secondary, each 1-2 hour, collecting decoction; Filter, filtrate decompression is condensed into thick paste, drying; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Prescription six: choose Radix Salviae Miltiorrhizae, Folium Ginkgo respectively, decocte with water secondary, each 1-2 hour, collecting decoction; Filter, filtrate decompression is condensed into thick paste, drying; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Prescription seven: choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Fructus Crataegi respectively, decocte with water secondary, each 1-2 hour, collecting decoction; Filter, filtrate decompression is condensed into thick paste, drying; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Prescription eight: choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Rhizoma Chuanxiong respectively, decocte with water secondary, each 1-2 hour, collecting decoction; Filter, filtrate decompression is condensed into thick paste, drying; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Prescription nine: choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Radix Puerariae respectively, decocte with water secondary, each 1-2 hour, collecting decoction; Filter, filtrate decompression is condensed into thick paste, drying; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Prescription ten: choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Folium Nelumbinis respectively, decocte with water secondary, each 1-2 hour, collecting decoction; Filter, filtrate decompression is condensed into thick paste, drying; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Effect experiment:
Experiment is divided into groups and the dosage design, and laboratory animal is divided into 22 groups at random, 12 every group: 1 technology of filling a prescription, 1 whole water are carried, technology 2 part water are carried+and three groups of high, medium and low dosage of alcohol extraction; The whole water of 2 technologies 1 of filling a prescription improve, in, three groups of low dosages; Dosage is each one group in prescription 3 to the prescription 10, with GUANXIN DANSHEN JIAONANG group, Composite Salvia Dropping Pill group, and Isosorbide fat group, model group, sham operated rats are relatively.
1. animal pattern is organized: get 264 of rats, rat is divided into 22 groups every group 12 at random.Every group of rat measured electrocardiogram and record respectively before coronary ligation, electrocardiogram is abnormal simultaneously eliminates.192 rats all get into next step test as a result.Administration 7 days, after the administration in the 7th day 1 hour, with 3% pentobarbital sodium (30 μ g/g intraperitoneal anesthesia rats.Chest QUMAO, sterilization along left mid-clavicular line longitudinal incision skin, separate basic unit in the 4th intercostal passivity, open the thoracic cavity; Cut off pericardium, gently press the right side thorax, draw out heart with the aluminum circle of providing for oneself then, carefully do not hurt left auricle; Have the part animal to ask at left auricle lower edge and pulmonary conus and can see left coronary artery anterior descending branch initial part, with being installed with the sutural 3/8 looper hook of 5-0 behind the ramus descendens anterior arteriae coronariae sinistrae trunk, depth of needle is controlled at 0.1cm rapidly; Width is 0.1～0.2cm, and the ligation arteria coronaria is put back to the thoracic cavity to heart; Push the thoracic cavity gently and extrude intrathoracic air, seal thoracic wall with mosquito forceps rapidly, wait and breathe stable back reuse suture.Variation person is not superseded for ECG ST section behind the ligation 10min.Postoperative lumbar injection penicillin sodium 2 * 105U/d, 5d infection continuously.
2. sham operated rats: only ask that at left auricle lower edge and pulmonary conus left coronary artery anterior descending branch position gets onesize pin suture needle and do not tie a knot, surplus operation and surgical groups with.
3. GUANXIN DANSHEN JIAONANG group: 12 of laboratory animals.Carry out modeling according to model production method, and before modeling, irritate clothes GUANXIN DANSHEN JIAONANG dissolution fluid (0.027g crude drug/100g body weight is equivalent to people's 6 times of clinical consumption consumptions).Successive administration 7 days.
4. Composite Salvia Dropping Pill group: 12 of laboratory animals.Carry out modeling according to model production method, and before modeling, irritate clothes FUFANG DANSHEN DIWAN dissolution fluid (the 0.81mg/100g body weight is equivalent to people's 6 times of clinical consumption consumptions).Successive administration 7 days.
5. Isosorbide fat group: 12 of laboratory animals.Carry out modeling according to model production method, and before modeling, irritate clothes Isosorbide liposoluble fluid (the 0.25mg/100g body weight is equivalent to people's 6 times of clinical consumption consumptions).Successive administration 7 days.
6. the 1 whole water of filling a prescription improve dose groups: 12 of laboratory animals.Carry out modeling according to model production method, and before modeling, irritate clothes prescription 1 whole water and carry medicinal liquid (2.76g crude drug/100g body weight is equivalent to people's 12 times of clinical consumption consumptions).Successive administration 7 days.
7. the 1 whole water of filling a prescription are put forward middle dose groups: 12 of laboratory animals.Carry out modeling according to model production method, and before modeling, irritate clothes prescription 1 whole water and carry medicinal liquid (1.38g crude drug/100g body weight is equivalent to people's 6 times of clinical consumption consumptions).Successive administration 7 days.
8. the 1 whole water of filling a prescription are put forward low dose group: 12 of laboratory animals.Carry out modeling according to model production method, and before modeling, irritate clothes prescription 1 medicinal liquid (0.69g crude drug/100g body weight is equivalent to people's 3 times of clinical consumption consumptions).Successive administration 7 days.
9. the 1 part water of filling a prescription carries+and alcohol extraction, prescription 2 to prescription 10 carry out administration as prescription 1 whole water sides of carrying.
Detect index: 1) electrocardiogram: behind the 10min, respectively survey electrocardiogram behind the modelling 21h one time after the modelling, write down 10min respectively after, ST value behind the 21h, calculate the value (ST section value of raising behind the Δ ST=10minST section value of raising-21h) of Δ ST simultaneously.
2) myocardial infarction area that causes of myocardial ischemia: behind the modelling 21h, use 3% pentobarbital sodium (30 μ g/g) intraperitoneal anesthesia rat once more, electrocardiogram and myocardium enzyme and MDA sampling are finished; Inject 10% potassium chloride 1ml from left ventricular catheter, make heart stop at relaxing period, inject with the blue 2ml of 5% Evans again; To distinguish the heart infarction district (not dyeing) and the non-heart infarction district of cardiac muscle; Cut heart at once, use the normal saline lavation, put into-4 ℃ of refrigerators after rinsing well freezing 30 minutes.Make serial section with left chamber axis; Every at a distance from one of 2mm; Put into 37 ℃ of water-bath 15min of N-BT phosphate buffer (pH7.4) of 0.1% then, put in the formaldehyde after taking out and wash, wait second day and take out again with behind the normal saline flushing; Uncoloured ischemia (ischemia) zone is carefully downcut, and claim weight in wet base.Dehydrogenase is lost because of cell membrane damage discharges fully in the infarcted myocardium cell, can not make the N-BT reduction stain, thereby infarcted myocardium is not colored, and remaining survival myocardium is then dyed blueness.Calculate ischemic myocardium with following formula and account for the percentage ratio of weight whole-heartedly: myocardial infarct size (%)=(not painted ischemic area weight in wet base/weight in wet base) whole-heartedly * 100%.
Experimental result is seen table 1, table 2:
Table 1: each is organized ECG ST section and changes (x ± s)
Annotate: first column data be respectively organize before the ligation the ST segment value, the secondary series data are ST section value of raising behind the ligation 10min, the 3rd classifies the clean drop-out value of ST section (ST section value of raising behind the Δ ST=10min ST section value of raising-21h) behind the 21h as.* compare with sham operated rats, P＜0.05, ▲ compare P＜0.05 with model group.
Experimental result shows: before the ligation before the administration each electrocardiogram all normal and do not have difference; Each group and sham operated rats compare behind the ligation 10min, and the modeling success of each group is explained in P＜0.05; Behind the ligation 21h, the ST section descends, and dropping distance is obvious with the medication group; Isosorbide fat sheet group particularly, Radix Salviae Miltiorrhizae group, the high, normal, basic dose groups of painstaking effort tube side; With model group relatively, P＜0.05 explain that respectively organizing medicine all has the effect that improves electrocardiogram variation due to the myocardial ischemia.
Table 2: each organizes the comparison (x ± s) of myocardial infarction area
Annotate: * and model group be P＜0.05. relatively
Experimental result shows: prescription 1 whole water are carried and the 1 part water of filling a prescription is carried+the high, medium and low dosage of part alcohol extraction and fill a prescription 2 to the dosage in 10 of filling a prescription in the painstaking effort tube side; The FUFANG DANSHEN DIWAN drop pill, Isosorbide fat sheet, GUANXIN DANSHEN JIAONANG; Taken 7 days continuously; Can obviously reduce the caused myocardial infarction area of rat heart muscle ischemia due to the ligation rat arteria coronaria, with model group relatively, P＜0.05.
Experimental example 2: the sharp wildcard side of heart and brain is to the protective effect research of acute cerebral ischemia.
Experiment is divided into groups and the dosage design, and laboratory animal is divided into 21 groups at random, 10 every group: 1 technology of filling a prescription, 1 whole water are carried, technology 2 part water are carried+and three groups of high, medium and low dosage of alcohol extraction; The whole water of 2 technologies 1 of filling a prescription improve, in, three groups of low dosages; Dosage is each one group in prescription 3 to the prescription 10, and with NIAOXUEKANG KOUFUYE group, the logical group of blood stasis dispelling, model control group, normal control group are relatively.
1. animal pattern group: get 210 of 150～170g rats, be divided into 21 groups at random, 1h gastric infusion every day is 1 time before preceding 8 days of experiment to art, except that the normal control group, respectively organizes equal ligation rat bilateral common carotid arteries, causes the incomplete ischemia of acute experiment property, puts to death behind the 3h.
2. NIAOXUEKANG KOUFUYE group: 10 of laboratory animals.Carry out modeling according to model production method, and before modeling, irritate clothes NIAOXUEKANG KOUFUYE (30ml/kg), successive administration 8 days.
3. blood stasis dispelling is logical organizes: 10 of laboratory animals.Carry out modeling according to model production method, and before modeling, irritate clothes blood stasis dispelling logical (2g/kg), successive administration 8 days
4. the 1 whole water of filling a prescription improve dose groups: 10 of laboratory animals.Carry out modeling according to model production method, and before modeling, irritate clothes prescription 1 whole water and carry medicinal liquid (2.76g crude drug/100g body weight is equivalent to people's 12 times of clinical consumption consumptions).Successive administration 8 days.
5. the 1 whole water of filling a prescription are put forward middle dose groups: 10 of laboratory animals.Carry out modeling according to model production method, and before modeling, irritate clothes prescription 1 whole water and carry medicinal liquid (1.38g crude drug/100g body weight is equivalent to people's 6 times of clinical consumption consumptions).Successive administration 8 days.
6. the 1 whole water of filling a prescription are put forward low dose group: 10 of laboratory animals.Carry out modeling according to model production method, and before modeling, irritate clothes prescription 1 medicinal liquid (0.69g crude drug/100g body weight is equivalent to people's 3 times of clinical consumption consumptions).Successive administration 8 days.
7. the 1 part water of filling a prescription carries+and alcohol extraction, prescription 2 to prescription 10 carry out administration as prescription 1 whole water sides of carrying.
Detect index: 1) cerebral edema: get 3h and put to death animal and get brain and weigh, roasting to constant weight in 110 ℃ of baking boxs, calculate brain water content and cerebral index.
2) cerebrovascular permeability: treating excess syndrome is tested animal; According to the said method modeling, and before model preparation 5min intravenous injection 50mg/kg Azo-Blue, get brain behind the execution rat and be dipped in the formamide solution; Temperature is bathed 72h in 45 ℃ of calorstats; Immersion utilizes the spectrophotometer colorimetric, and (wavelength=620nm), calculate Azo-Blue content in the brain according to standard curve is heavily represented with the ug/g cutaneous horn.
Experimental result is seen table 3, table 4:
Table 3: each organizes the influence (x ± s) of experimental cerebral ischemia
Annotate: compare * P＜0.05, * * P＜0.01 with normal group; With model group comparison ▲ P＜0.05 (down together).
Table 4: each group is to the influence of experimental imperfection ischemia cerebrovascular permeability (x ± s)
Experimental result shows: through the influence to observation cerebral edema and cerebrovascular permeability, each fill a prescription dose groups and model group and normal control group more all have remarkable result and have statistical significance.Acute cerebral ischemia had protective effect.
Composite whether certain effect arranged all for what study Radix Salviae Miltiorrhizae, Folium Ginkgo, Radix Notoginseng, Radix Puerariae, Rhizoma Chuanxiong, Fructus Crataegi, Folium Nelumbinis, augment following experimental program again, extraction process and model method are with reference to the preamble corresponding position:
Fill a prescription 11:
5 parts of Radix Salviae Miltiorrhizaes, 50 parts of Folium Ginkgos, 3 parts of Radix Notoginseng,
15 parts of Radix Puerariaes, 15 parts of Rhizoma Chuanxiongs, 50 parts of Fructus Crataegis,
50 parts on Folium Nelumbinis.
Fill a prescription 12:
50 parts of Radix Salviae Miltiorrhizaes, 5 parts of Folium Ginkgos, 50 parts of Radix Notoginseng,
5 parts of Radix Puerariaes, 5 parts of Rhizoma Chuanxiongs, 50 parts of Fructus Crataegis,
5 parts on Folium Nelumbinis.
Fill a prescription 11 or 12 the 1st kind of technology of filling a prescription, choose Radix Salviae Miltiorrhizae, Folium Ginkgo, Radix Notoginseng, Radix Puerariae, Rhizoma Chuanxiong, Fructus Crataegi, Folium Nelumbinis respectively, decocte with water secondary, each 1-2 hour; Collecting decoction filters, and filtrate decompression is condensed into thick paste; Dry; Be ground into fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Fill a prescription 11 or 12 the 2nd kind of technology of filling a prescription, choose Radix Salviae Miltiorrhizae, Radix Notoginseng, Rhizoma Chuanxiong, Folium Nelumbinis respectively, the decocte with water secondary, each 1-2 hour, collecting decoction filtered, and filtrate decompression is condensed into thick paste, and drying is ground into fine powder, and is subsequent use; Choose Folium Ginkgo, Radix Puerariae, Fructus Crataegi, add 6-10 and doubly measure 60% ethanol extraction secondary, each 1-2 hour, filter, decompression filtrate recycling ethanol is condensed into the thick paste shape, and drying is ground into fine powder; Merge with above-mentioned fine powder, add conventional adjuvant and process clinical acceptable forms, like dosage forms such as tablet, capsule, granules.
Table 5: each organizes the influence (x ± s) of experimental cerebral ischemia
Claims (5)
1. the heart and brain profit is led to preparation, it is characterized in that: be the medicament of being processed by following Chinese medicine raw materials by weight proportion:
25 parts of Radix Salviae Miltiorrhizaes, 15 parts of Folium Ginkgos, 3 parts of Radix Notoginseng,
25 parts of Radix Puerariaes, 20 parts of Rhizoma Chuanxiongs, 25 parts of Fructus Crataegis,
20 parts on Folium Nelumbinis.
2. the heart and brain profit is led to preparation, it is characterized in that: be the medicament of being processed by following Chinese medicine raw materials by weight proportion:
25 parts of Radix Salviae Miltiorrhizaes, 15 parts of Folium Ginkgos, 3 parts of Radix Notoginseng,
25 parts of Radix Puerariaes, 20 parts of Rhizoma Chuanxiongs, 25 parts of Fructus Crataegis.
3. the heart and brain profit is led to preparation, it is characterized in that: be the medicament of being processed by following Chinese medicine raw materials by weight proportion:
50 parts of Radix Salviae Miltiorrhizaes, 15 parts of Folium Ginkgos, 3 parts of Radix Notoginseng,
25 parts of Radix Puerariaes, 20 parts of Rhizoma Chuanxiongs.
4. the heart and brain profit is led to preparation, it is characterized in that: be the medicament of being processed by following Chinese medicine raw materials by weight proportion:
5 parts of Radix Salviae Miltiorrhizaes, 50 parts of Folium Ginkgos, 3 parts of Radix Notoginseng,
15 parts of Radix Puerariaes, 15 parts of Rhizoma Chuanxiongs, 50 parts of Fructus Crataegis,
50 parts on Folium Nelumbinis.
5. the heart and brain profit is led to preparation, it is characterized in that: be the medicament of being processed by following Chinese medicine raw materials by weight proportion:
50 parts of Radix Salviae Miltiorrhizaes, 5 parts of Folium Ginkgos, 50 parts of Radix Notoginseng,
5 parts of Radix Puerariaes, 5 parts of Rhizoma Chuanxiongs, 50 parts of Fructus Crataegis,
5 parts on Folium Nelumbinis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810136660 CN101524421B (en) | 2008-12-31 | 2008-12-31 | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810136660 CN101524421B (en) | 2008-12-31 | 2008-12-31 | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101524421A CN101524421A (en) | 2009-09-09 |
| CN101524421B true CN101524421B (en) | 2012-01-11 |
Family
ID=41092596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810136660 Expired - Fee Related CN101524421B (en) | 2008-12-31 | 2008-12-31 | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101524421B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103223031A (en) * | 2013-05-06 | 2013-07-31 | 陕西立众制药有限公司 | Traditional Chinese medicinal composition for tonifying kidney, downbearing turbidity, invigorating blood circulation and relieving pain and preparation method thereof |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670978B (en) * | 2012-06-06 | 2017-12-19 | 张旺凡 | A kind of polygonatum compound granule and preparation method thereof |
| CN102973821A (en) * | 2012-08-21 | 2013-03-20 | 苏州谷力生物科技有限公司 | Composition having vascular headache improvement effect |
| CN103961402A (en) * | 2013-01-28 | 2014-08-06 | 钟大德 | Traditional Chinese medicine decoction for promoting blood circulation and production method thereof |
| CN103432200B (en) * | 2013-09-16 | 2016-03-09 | 云南楚雄天利药业有限公司 | A kind of medicine for the treatment of Orthopeadic Surgery disease |
| CN103989758A (en) * | 2014-06-17 | 2014-08-20 | 史克勇 | Pharmaceutical composition for relieving myocardial ischemia |
| CN103989808A (en) * | 2014-06-17 | 2014-08-20 | 史克勇 | Compound granule |
| CN104000884A (en) * | 2014-06-17 | 2014-08-27 | 史克勇 | Pharmaceutical composition for relieving myocardial ischemia |
| CN104042735A (en) * | 2014-06-19 | 2014-09-17 | 史克勇 | Medicament for alleviating myocardial ischemia |
| CN104000871A (en) * | 2014-06-19 | 2014-08-27 | 史克勇 | Drug for treating myocardial ischemia |
| CN104905248A (en) * | 2015-05-15 | 2015-09-16 | 周新福 | Health-care tea for preventing cerebrovascular disease and preparation method of health-care tea |
| CN105380996B (en) * | 2015-11-10 | 2021-02-02 | 石任兵 | Traditional Chinese medicine composition with blood circulation promoting and bleeding stopping effects and preparation thereof |
| CN105596794A (en) * | 2016-01-04 | 2016-05-25 | 季一艮 | Traditional Chinese medicine composition for treating three high disease |
| CN105748638A (en) * | 2016-04-26 | 2016-07-13 | 陶章菊 | Heart and cerebral vessel dredging formula |
| CN110934985A (en) * | 2020-01-06 | 2020-03-31 | 回春堂药业股份有限公司 | A Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases, and its preparation method |
| CN116211974B (en) * | 2022-12-08 | 2024-02-23 | 河南省药品医疗器械检验院(河南省疫苗批签中心) | Traditional Chinese medicine composition for improving microcirculation of human body |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1224614A (en) * | 1998-01-24 | 1999-08-04 | 倪德贵 | Medicine for preventing and curing cardiac and cerebral vascular diseases and its preparation |
| CN100348223C (en) * | 2005-11-01 | 2007-11-14 | 山东省中医药研究院 | Medicine for treating ischemic cerebral disease and its prepn |
-
2008
- 2008-12-31 CN CN 200810136660 patent/CN101524421B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1224614A (en) * | 1998-01-24 | 1999-08-04 | 倪德贵 | Medicine for preventing and curing cardiac and cerebral vascular diseases and its preparation |
| CN100348223C (en) * | 2005-11-01 | 2007-11-14 | 山东省中医药研究院 | Medicine for treating ischemic cerebral disease and its prepn |
Non-Patent Citations (4)
| Title |
|---|
| 何燕等.中医药防治中风及脑缺血再灌注损伤的研究概况.《中国药房》.2005,第16卷(第02期), * |
| 文静等.脑缺血再灌注损伤中医药防治研究进展.《中国中医急症》.2007,第16卷(第06期), * |
| 潘赞红等.中医药对心肌缺血再灌注损伤保护作用研究概况.《天津药学》.2008,第20卷(第04期), * |
| 章常华等.抗心肌缺血天然产物研究进展.《中药材》.2003,第26卷(第04期), * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103223031A (en) * | 2013-05-06 | 2013-07-31 | 陕西立众制药有限公司 | Traditional Chinese medicinal composition for tonifying kidney, downbearing turbidity, invigorating blood circulation and relieving pain and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101524421A (en) | 2009-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101524421B (en) | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases | |
| CN102362881A (en) | Method for preparing ginkgo and American ginseng preparation | |
| CN101524469B (en) | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof | |
| CN102940801A (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN101804110B (en) | Traditional Chinese medicine preparation for thrombosis and blood lipid | |
| CN101524470B (en) | Traditional Chinese medicine preparation for curing angiocardiopathy stent restenosis and preparation method thereof | |
| CN103479754B (en) | Hypotensive drug and preparation method thereof | |
| CN102726708A (en) | Health-care food for lowering blood pressure | |
| CN104687198A (en) | Health beverage with Qi tonifying and nerve soothing effects and preparing method | |
| CN102068520B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN103005448B (en) | Health-care food composition for improving anoxia endurance and preparation method thereof | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN102920837A (en) | Traditional Chinese medicine for treating arrhythmia and preparation process and application thereof | |
| CN101062027B (en) | Taurine and medical combination for treating cardiovascular and cerebrovascular diseases | |
| CN106938048A (en) | A kind of Chinese medicine preparation for treating cardiovascular and cerebrovascular disease | |
| CN103027944A (en) | Pharmaceutical composition for preventing and treating cardiovascular and cerebrovascular disease | |
| CN103055122B (en) | The medicine and preparation method thereof of restenosis after prevention percutaneous transluminal coronary stent implantation | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN101744938B (en) | Pharmaceutical composition and preparation method thereof | |
| CN102008571B (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN101623325B (en) | Ziziphora clinopodioides Lam. total flavonoid extract and production method thereof and application thereof in cardiovascular drug | |
| CN101199568A (en) | Medicament compound for treating cardiovascular disease and preparing method thereof | |
| CN100546637C (en) | A kind of Chinese medicine composition for the treatment of coronary heart disease and preparation method thereof | |
| CN102772665B (en) | Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANXI YABAO PHARMACEUTICAL GROUP CORP. Free format text: FORMER OWNER: BENCAO TIAN'GONG SCIENCE + TECH. CO., LTD., JIANGXI Effective date: 20130729 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 330006 NANCHANG, JIANGXI PROVINCE TO: 044600 YUNCHENG, SHAANXI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130729 Address after: 044600 Fumin Road, Ruicheng County, Shanxi, China, No. 43, No. Patentee after: Shanxi Yabao Pharmaceutical Group Corp. Address before: 330006 experimental building, No. 56 Yangming Road, Jiangxi, Nanchang Patentee before: Bencao Tian'gong Science & Tech. Co., Ltd., Jiangxi |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190108 Address after: 330006 No. 56 Yangming Road, Donghu District, Nanchang City, Jiangxi Province Patentee after: Bencao Tian'gong Science & Tech. Co., Ltd., Jiangxi Address before: 044600 43 Fumin Road, Ruicheng County, Yuncheng, Shanxi Patentee before: Shanxi Yabao Pharmaceutical Group Corp. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120111 Termination date: 20191231 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |